's wholly owned US subsidiary InvaGen Pharmaceuticals received 2 inspection observations in Form 483 from the USFDA following a Pre-Approval Inspection conducted from February 2nd to 9th, 2026 at its Hauppauge, New York manufacturing facility. The company has committed to working closely with the USFDA to address these observations comprehensively within the stipulated timeframe and has notified stock exchanges as per regulatory requirements. Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations.